To include your compound in the COVID-19 Resource Center, submit it here.

May 12 Quick Takes: Skyhawk, Merck expand deal; plus Sanofi’s Sarclisa and clinical updates drive gains for Gamida, CymaBay

Autoimmune, metabolic diseases added to Skyhawk-Merck deal
Skyhawk Therapeutics Inc. expanded a collaboration with Merck & Co. Inc. (NYSE:MRK) to discover and develop small molecules that modulate RNA

Read the full 279 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE